Tokyo, Japan

Yoshio Arakawa

This inventor holds 1 USPTO granted patent. Top assignee: Numab Therapeutics Ag. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yoshio Arakawa. Retrieved from https://idiyas.com/inventor/yoshio-arakawa-zbcknaf5

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Yoshio Arakawa

Introduction

Yoshio Arakawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of multispecific antibodies. His work has the potential to impact therapeutic approaches for various diseases.

Latest Patents

Yoshio Arakawa holds a patent for "Multispecific Antibodies Having Specificity for IL-4R and IL-31, Encoding Nucleic Acids Thereof and Methods of Treating." This patent represents a significant advancement in the treatment of conditions related to these interleukins.

Career Highlights

Arakawa is currently associated with Numab Therapeutics AG, where he continues to innovate in the field of antibody development. His expertise and dedication have positioned him as a key figure in his organization.

Collaborations

He collaborates with talented individuals such as Julia Tietz and Tea Gunde, contributing to a dynamic research environment that fosters innovation.

Conclusion

Yoshio Arakawa's work exemplifies the spirit of innovation in biotechnology. His contributions through patents and collaborations are paving the way for future advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…